PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CN108601841) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS

Office : China
Application Number: 201780008716.8 Application Date: 10.02.2017
Publication Number: 108601841 Publication Date: 28.09.2018
Publication Kind : A
Prior PCT appl.: Application Number:PCTUS2017017435 ; Publication Number: Click to see the data
IPC:
A61K 45/06
C07K 16/30
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants: IMMUNOMEDICS INC
免疫医疗公司
Inventors: CHANG CHIEN-HSING
张健行
GOLDENBERG DAVID M
D.M.戈尔登贝格
Agents: 中国专利代理(香港)有限公司 72001
中国专利代理(香港)有限公司 72001
Priority Data: 62/293530 10.02.2016 US
62/329788 29.04.2016 US
62/336985 16.05.2016 US
Title: (EN) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
(ZH) ABCG2抑制剂与SACITUZUMAB GOVITECAN(IMMU-132)的组合克服表达TROP-2的癌中对SN-38的抗性
Abstract: front page image
(EN) The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibodyor fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combinationwith an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.
(ZH) 本发明涉及治疗性ADCs,其包含与抗癌抗体或抗原结合抗体片段连接的药物。优选地,所述药物是SN‑38。更优选地,所述抗体或其片段结合于Trop‑2,并且所述治疗用于治疗Trop‑2阳性癌。最优选地,所述抗体是hRS7。所述ADC与ABCG2抑制剂组合施用于患有癌的受试者。所述组合治疗可以有效治疗对单独的药物和/或对单独的ADC有抗性的癌。
Also published as:
CA3011372IN201817027046EP3413914WO/2017/139623